SEARCH

SEARCH BY CITATION

  • 1
    Shelton GD. Canine myasthenia gravis. In: KirkRW, BonaguraJD, eds. Current Veterinary Therapy, 11th ed. Philadelphia , PA : WB Saunders; 1992:10391042.
  • 2
    Lindstrom J., Shelton D., Fujii Y. Myasthenia gravis. Adv Immunol 1987;42:233284.
  • 3
    Shelton GD. Disorders of neuromuscular transmission. Semin Vet Med Surg (Small Anim) 1989;4:126132.
  • 4
    Elias SB, Appel SH. Current concepts of pathogenesis and treatment of myasthenia gravis. Med Clin North Am 1979;63:745757.
  • 5
    Pedroia V. Disorders of the skeletal muscles. In: EttingerSJ, ed. Textbook of Veterinary Internal Medicine. Philadelphia , PA : WB Saunders; 1989:733744.
  • 6
    Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:17971810.
  • 7
    Shelton GD, Cardinet GH, Lindstrom JM. Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptor. Neurology 1988;38:14171424.
  • 8
    Lennon VA, Lambert E., Palmer AC, et al. Acquired and congenital myasthenia gravis in dogs: A study of 20 cases. In: SatoyoshiE., ed. Myasthenia Gravis: Pathogenesis and Treatment. Tokyo : University of Tokyo Press; 1981:4154.
  • 9
    DeBaets MH, Kuks JJM. Immunopathology of myasthenia gravis. In: DeBaetsMH, OosterhuisHJGH, eds. Myasthenia Gravis. London : CRC Press; 1993:147181.
  • 10
    Watson DF, Lisak RP. Myasthenia gravis: An overview. In: LisakRP, ed. Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York : Marcel Dekker; 1994:119.
  • 11
    Shelton GD. Megaesophagus secondary to acquired myasthenia gravis. In: KirkRW, BonaguraJD, eds. Current Veterinary Therapy, 11th ed. Philadelphia , PA : WB Saunders; 1992:580583.
  • 12
    Oosterhuis HJGH. Clinical aspects. In: DeBaetsMH, OosterhuisHJGH, eds. Myasthenia Gravis. London : CRC Press; 1993:1342.
  • 13
    Levin KH, Richman DP. Myasthenia gravis. In: AdachiM., SherJH, eds. Current Trends in Neurosciences: Neuromuscular Disease. New York : Igaku-Shoin; 1990:296317.
  • 14
    Swash M., Schwartz M. Myasthenia gravis and other myasthenic syndromes. In: SwashM., SchwartzM., eds. Neuromuscular Diseases: A Practical Approach to Diagnosis and Management. New York : Springer-Verlag; 1988:229250.
  • 15
    Lisak RP, Barchi RL. Myasthenia gravis. In: WaltonJN, ed. Major Problems in Neurology. Philadelphia : WB Saunders; 1982:536.
  • 16
    Sanders DB, Howard JF. Disorders of neuromuscular transmission. In: BradleyWG, DaroffRB, FenichelGM, MarsdenCD, eds. Neurology in Clinical Practice: The Neurological Disorders. Boston : Butterworth-Heinemann; 1991:18191842.
  • 17
    Hebra AE, Reed CE, Heldmann M., et al. Myasthenia gravis: A review with emphasis on the potential role of thymectomy. J South Carolina Med Assoc 1990;July:392396.
  • 18
    Sergott RC. Ocular myasthenia. In: LisakRP, ed. Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York : Marcel Dekker; 1994:2131.
  • 19
    Shelton GD, Willard MD, Cardinet GH, et al. Acquired myasthenia gravis: Selective involvement of esophageal, and facial muscles. J Vet Intern Med 1990;4:281284.
  • 20
    Sims MH, McLean RA. Use of repetitive nerve stimulation to assess neuromuscular function in dogs: A test protocol for suspected myasthenia gravis. Prog Vet Neurol 1990;1:311319.
  • 21
    Pflugfelder CM, Cardinet GH, Lutz H., et al. Acquired canine myasthenia gravis: Immunocytochemical localization of immune complexes at neuromuscular junctions. Muscle Nerve 1981;4:289295.
  • 22
    Daniel WW. Biostatistics: A Foundation for Analysis in the Health Sciences, 4th ed. New York : John Wiley and Sons; 1987.
  • 23
    Agresti A. Categorical Data Analysis. New York : John Wiley and Sons; 1990.
  • 24
    Harris EK. Survivorship Analysis for Clinical Studies. New York : Marcel Dekker; 1991.
  • 25
    Soliven BC, Lange DJ, Perm AS, et al. Seronegative myasthenia gravis. Neurology 1988;38:514517.
  • 26
    Shelton GD. Canine seronegative acquired myasthenia gravis. Proceedings of the 7th ACVIM Forum, May 1989:9991002.
  • 27
    Palmer AC. Myasthenia gravis. Vet Clin North Am Small Anim Pract 1980;10:213221.
  • 28
    Bellah JR, Stiff ME, Russell RG. Thymoma in the dog: Two case reports and review of 20 additional cases. J Am Vet Med Assoc 1983;183:306311.
  • 29
    Aronsohn MG, Schunk KL, Carpenter JL, et al. Clinical and pathologic features of thymoma in 15 dogs. J Am Vet Med Assoc 1984;184:13551362.
  • 30
    Klebanow ER. Thymoma and acquired myasthenia gravis in the dog: A case report and review of 13 additional cases. J Am Anim Hosp Assoc 1992;28:6369.
  • 31
    Atwater SW, Powers BE, Park RD, et al. Thymoma in dogs: 23 cases (1980–1991). J Am Vet Med Assoc 1994;205:10071013.
  • 32
    Ouchi M., Shoji Y., Yoshida I., et al. Experience in the treatment of acute fulminating myasthenia gravis. J Jap Assoc Thorac Surg 1992;40:265272.
  • 33
    Oh SJ, Eslami N., Nishihira T., et al. Electrophysiological and clinical correlation in myasthenia gravis. Ann Neurol 1982;12:348354.
  • 34
    Oda K., Shibasaki H. Antigenic difference of acetylcholine receptor between single and multiple form endplates of human extraocular muscle. Brain Res 1988;449:337340.
  • 35
    Drachman DB, Adams RN, Josifek LF, et al. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982;307:769775.
  • 36
    Braund KG. Neurological diseases. In: BraundKG, ed. Clinical Syndromes in Veterinary Neurology, 2nd ed. St Louis : Mosby-Year Book; 1994.